Mankind Pharma has debuted at Rs 1300.00 on the BSE, up by 220 points or 20.37% from its issue price of Rs 1080.
The scrip is currently trading at Rs 1388.30, up by 308.30 points or 28.55% from its issue price. It has touched a high and low of Rs 1395.00 and Rs 1300.00 respectively. So far 7.19 lakh shares were traded on the counter.
The offering, which was open for subscription between April 25, 2023 and April 27, 2023 was subscribed over 15 times. The issue price was fixed at Rs 1080 per share i.e. at upper end of price band of Rs 1026-1080 apiece.
Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: